Compare · ABOS vs MRNA
ABOS vs MRNA
Side-by-side comparison of Acumen Pharmaceuticals Inc. (ABOS) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABOS and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $19.80B, about 115.7x ABOS ($171.2M).
- Over the past year, ABOS is up 121.5% and MRNA is up 87.2% - ABOS leads by 34.3 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 10 for ABOS).
- MRNA has more recent analyst coverage (25 ratings vs 12 for ABOS).
- Company
- Acumen Pharmaceuticals Inc.
- Moderna Inc.
- Price
- $2.37-0.21%
- $49.94+0.56%
- Market cap
- $171.2M
- $19.80B
- 1M return
- -5.01%
- -0.94%
- 1Y return
- +121.50%
- +87.20%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2018
- News (4w)
- 10
- 15
- Recent ratings
- 12
- 25
Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest ABOS
- Director Fountain Nathan B sold $14,273 worth of shares (6,400 units at $2.23), decreasing direct ownership by 12% to 48,150 units (SEC Form 4)
- Director Ra Capital Management, L.P. was granted 35,500 shares (SEC Form 4)
- Director Fountain Nathan B was granted 35,500 shares, increasing direct ownership by 186% to 54,550 units (SEC Form 4)
- Director Drapkin Kimberlee C was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)
- Director Stalfort John A Iii was granted 35,500 shares, increasing direct ownership by 19% to 220,624 units (SEC Form 4)
- Director Porter Derrell was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)
- Director Ives Jeffrey L. was granted 35,500 shares, increasing direct ownership by 277% to 48,300 units (SEC Form 4)
- Director Golumbeski George was granted 35,500 shares (SEC Form 4)
- Director Stoppel Laura was granted 35,500 shares (SEC Form 4)
- Acumen Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability